Icon (NASDAQ:ICLR) Price Target Raised to $130.00

Icon (NASDAQ:ICLR) had its price objective raised by investment analysts at JPMorgan Chase & Co. from $120.00 to $130.00 in a report released on Friday,Benzinga reports. The brokerage presently has a “neutral” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s target price would suggest a potential downside of 3.72% from the stock’s previous close.

ICLR has been the subject of a number of other reports. Royal Bank Of Canada restated a “sector perform” rating and set a $126.00 target price on shares of Icon in a research report on Friday. Weiss Ratings downgraded shares of Icon from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, March 18th. Zacks Research downgraded Icon from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 25th. Barclays boosted their price target on Icon from $120.00 to $150.00 and gave the company an “equal weight” rating in a report on Friday. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Icon in a report on Friday. Seven investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, Icon currently has an average rating of “Hold” and a consensus target price of $153.87.

Icon Stock Performance

Shares of Icon stock traded down $1.78 on Friday, reaching $135.02. 353,224 shares of the stock were exchanged, compared to its average volume of 1,587,411. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. Icon has a twelve month low of $66.57 and a twelve month high of $211.00. The firm has a market capitalization of $10.90 billion, a price-to-earnings ratio of 21.92, a PEG ratio of 3.09 and a beta of 1.23. The business has a 50 day moving average price of $112.28 and a two-hundred day moving average price of $141.50.

Icon (NASDAQ:ICLR) last posted its earnings results on Wednesday, May 27th. The medical research company reported $2.52 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.95 by ($0.43). The business had revenue of $2.11 billion for the quarter, compared to analyst estimates of $1.98 billion. Icon had a net margin of 7.40% and a return on equity of 10.58%. The company’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.43 earnings per share. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. Analysts anticipate that Icon will post 11.53 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Muhlenkamp & Co. Inc. purchased a new stake in Icon in the 3rd quarter valued at $12,857,000. Mitchell Capital Management Co. purchased a new stake in Icon in the 3rd quarter valued at $1,627,000. First National Bank of Omaha purchased a new stake in shares of Icon in the 3rd quarter valued at approximately $6,267,000. Allspring Global Investments Holdings LLC grew its stake in shares of Icon by 1.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,080,192 shares of the medical research company’s stock valued at $203,800,000 after buying an additional 11,335 shares during the period. Finally, CIBC Bancorp USA Inc. purchased a new stake in shares of Icon in the 3rd quarter valued at approximately $39,074,000. 95.61% of the stock is owned by institutional investors and hedge funds.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.